{
  "primary": "TARDBP",
  "interaction_type": "direct",
  "upstream_interactor": null,
  "mediator_chain": [],
  "depth": 1,
  "support_summary": "VCP is responsible for clearing pathological aggregates of TARDBP (TDP-43), a key protein in ALS and FTLD. This substrate relationship involves direct physical interaction.",
  "functions": [
    {
      "function": "Pathological Aggregate Clearance",
      "arrow": "activates",
      "cellular_process": "VCP/p97 is a critical component of the protein quality control system that recognizes and clears pathological, ubiquitinated aggregates of TARDBP (TDP-43). As an AAA+ ATPase segregase, VCP utilizes the energy from ATP hydrolysis to extract misfolded TDP-43 polypeptides from insoluble aggregates. This disaggregation step is a prerequisite for their subsequent degradation by either the ubiquitin-proteasome system or the autophagy-lysosome pathway.",
      "effect_description": "Acts as a segregase to disassemble ubiquitinated TDP-43 aggregates, thereby facilitating their degradation and preventing the neurotoxicity associated with TDP-43 proteinopathies like ALS and FTLD.",
      "biological_consequence": [
        "Neurodegenerative disease stress → TDP-43 mislocalizes, misfolds, and aggregates → TDP-43 aggregates become ubiquitinated → VCP and its cofactors are recruited to the ubiquitinated aggregates → VCP's ATPase activity unfolds and extracts TDP-43 from the aggregate → Solubilized TDP-43 is targeted for degradation by the 26S proteasome or autophagy → Clearance of toxic aggregates and mitigation of neurodegeneration."
      ],
      "specific_effects": [
        "VCP is essential for clearing stress-induced and disease-associated TDP-43 aggregates from both the nucleus and cytoplasm.",
        "Disease-causing mutations in VCP impair TDP-43 aggregate clearance, leading to their accumulation and contributing to the pathogenesis of ALS and FTLD.",
        "Pharmacological activation of VCP's ATPase activity enhances the clearance of insoluble TDP-43 aggregates."
      ],
      "evidence": [
        {
          "paper_title": "VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models",
          "journal": "Journal of Clinical Investigation",
          "year": 2024,
          "relevant_quote": "Consistent with a loss of nuclear VCP function, cells harboring MSP variants or cells treated with VCP inhibitor exhibited decreased clearance of insoluble intranuclear TDP-43 aggregates. Moreover, we identified 4 compounds that activate VCP primarily by increasing D2 ATPase activity, where pharmacologic VCP activation appears to enhance clearance of insoluble intranuclear TDP-43 aggregate.",
          "pmid": "38787785"
        }
      ],
      "pathway": {
        "name": "Aggrephagy",
        "canonical_name": "Aggrephagy",
        "ontology_id": "GO:0035973",
        "ontology_source": "GO",
        "confidence": 0.8
      },
      "pmids": [
        "38787785"
      ],
      "interaction_effect": "activates",
      "interaction_direction": "main_to_primary",
      "function_effect": "activation"
    }
  ],
  "arrow": "binds",
  "direction": "main_to_primary",
  "intent": "regulation",
  "arrows": {
    "main_to_primary": [
      "activates"
    ]
  },
  "is_valid": true,
  "mechanism_correction": null,
  "mechanism": "VCP/p97 is a critical component of the protein quality control system that recognizes and clears pathological, ubiquitinated aggregates of TARDBP (TDP-43). As an AAA+ ATPase segregase, VCP utilizes the energy from ATP hydrolysis to extract misfolded TDP-43 polypeptides from insoluble aggregates. This disaggregation step is a prerequisite for their subsequent degradation by either the ubiquitin-proteasome system or the autophagy-lysosome pathway.",
  "effect": "Acts as a segregase to disassemble ubiquitinated TDP-43 aggregates, thereby facilitating their degradation and preventing the neurotoxicity associated with TDP-43 proteinopathies like ALS and FTLD.",
  "summary": "VCP interacts with TARDBP to modulate pathological aggregate clearance, ultimately affecting clearance of toxic aggregates and mitigation of neurodegeneration.",
  "evidence": [
    {
      "paper_title": "VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models",
      "journal": "Journal of Clinical Investigation",
      "year": 2024,
      "relevant_quote": "Consistent with a loss of nuclear VCP function, cells harboring MSP variants or cells treated with VCP inhibitor exhibited decreased clearance of insoluble intranuclear TDP-43 aggregates. Moreover, we identified 4 compounds that activate VCP primarily by increasing D2 ATPase activity, where pharmacologic VCP activation appears to enhance clearance of insoluble intranuclear TDP-43 aggregate."
    },
    {
      "paper_title": "The VCP/p97 ATPase is required for clearance of TARDBP/TDP-43 aggregates",
      "journal": "Human Molecular Genetics",
      "year": 2013,
      "relevant_quote": "Here, we show that VCP is required for the clearance of stress-induced, cytoplasmic TDP-43-positive SGs and clearance of insoluble, ubiquitinated TDP-43. Pathogenic mutations in VCP lead to the accumulation of TDP-43-positive SGs and insoluble TDP-43."
    }
  ],
  "pathways": [
    {
      "name": "Aggrephagy",
      "canonical_name": "Aggrephagy",
      "ontology_id": "GO:0035973",
      "ontology_source": "GO",
      "confidence": 0.8
    }
  ],
  "interaction_effect": "binding",
  "_validation_metadata": {
    "validated": true,
    "validator": "arrow_effect_validator",
    "corrections_applied": 1
  },
  "_arrow_validated": true,
  "arrow_notation": "VCP --binds--> TARDBP:",
  "protein_a": "VCP",
  "protein_b": "TARDBP",
  "discovered_in_query": "VCP",
  "first_discovered": "2025-12-04T19:56:00.364685Z",
  "last_updated": "2025-12-04T19:56:00.364685Z"
}